1. U.S. Food and Drug Administration.Safety clinical trial shows possible increased risk of cancer with weight‐loss medicine Belviq Belviq XR (lorcaserin).https://www.fda.gov/drugs/drug‐safety‐and‐availability/safety‐clinical‐trial‐shows‐possible‐increased‐risk‐cancer‐weight‐loss‐medicine‐belviq‐belviq‐xr. Published January 14 2020. Updated February 13 2020.
2. U.S. Food and Drug Administration.FDA requests the withdrawal of the weight‐loss drug Belviq Belviq XR (lorcaserin) from the market.https://www.fda.gov/drugs/drug‐safety‐and‐availability/fda‐requests‐withdrawal‐weight‐loss‐drug‐belviq‐belviq‐xr‐lorcaserin‐market. Published February 13 2020.
3. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
4. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
5. U.S. Food and Drug Administration.BELVIQ: Highlights of prescribing information.https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022529lbl.pdf. Updated June 2012. Accessed February 24 2020.